Botulinum toxin (BTX) has been used at Baylor’s Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC) in the treatment of dystonia and related disorders since 1983. Its safety and efficacy ...

The company’s lead clinical candidate, BTX-A51, is an oral small molecule, multi-kinase inhibitor designed to block a specific leukemic stem cell target (CK1α) as well as super enhancer targets ...